HS
SNDX icon

HighVista Strategies’s Syndax Pharmaceuticals SNDX Stock Holding History

HighVista Strategies’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,519
Closed -$512K – 156
2024
Q1 		$512K Buy
+21,519
New +$480K 0.18% 117
2023
Q4 		– Sell
-29,490
Closed -$428K – 144
2023
Q3 		$428K Sell
29,490
-4,086
-12% -$77.3K 0.2% 122
2023
Q2 		$703K Buy
33,576
+7,972
+31% +$166K 0.32% 87
2023
Q1 		$541K Buy
25,604
+6,943
+37% +$173K 0.44% 71
2022
Q4 		$475K Sell
18,661
-18,443
-50% -$430K 0.28% 76
2022
Q3 		$892K Buy
+37,104
New +$832K 0.51% 46
2022
Q1 		– Sell
-38,347
Closed -$839K – 97
2021
Q4 		$839K Sell
38,347
-7,237
-16% -$134K 0.67% 55
2021
Q3 		$872K Sell
45,584
-2,230
-5% -$37.2K 0.58% 58
2021
Q2 		$821K Buy
47,814
+12,941
+37% +$237K 0.58% 37
2021
Q1 		$779K Buy
+34,873
New +$788K 0.58% 31

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

HighVista Strategies's SNDX Position: Q2 2024 in Review

HighVista Strategies sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 21,519 shares — an estimated $512K sold.

HighVista Strategies first reported a position in SNDX in Q1 2021 and held it in 10 quarters. The position peaked at $892K in Q3 2022. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

  • HighVista Strategies reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • HighVista Strategies sold 21,519 Syndax Pharmaceuticals shares in Q2 2024, an estimated $512K.
  • HighVista Strategies first reported a position in Syndax Pharmaceuticals in Q1 2021 and held it in 10 quarters.
  • HighVista Strategies's Syndax Pharmaceuticals position peaked at $892K in Q3 2022.
  • 196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.